Asian Spectator


The Times

.

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China

  • Written by ACN Newswire - Press Releases

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China

TOKYO, Feb 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China.

Based on this agreement, Eisai will acquire exclusive...

Magazine

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

hacklink hack forum hacklink film izle hacklink z-librarykingroyalmrkinggrandpashabetagen bolatelegram下载madridbetzlibrary.jojobetสล็อตสล็อตgrandpashabetstakejojobetTotalSportStreamEasthitbet girişbetasus girişcasibomjojobetjojobetkumar sitelerivipparkholiganbetholiganbet